close

Trimeris, Inc., a biopharmaceutical company, engages primarily in the commercialization of a class of fusion inhibitors for antiviral drug treatments. Its fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate, and infect host cells. The company offers FUZEON, a human immunodeficiency virus (HIV) fusion inhibitor and a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41 under a collaboration with F. Hoffmann-La Roche Ltd. Its FUZEON inhibitor blocks HIV viral fusion by interfering with certain structural rearrangements within gp41 that are required for HIV to fuse to and enter a host cell. FUZEON is approved in the United States, Canada, and the European Union. The company also holds TRI-1144, a next generation fusion inhibitor candidate that completed Phase I clinical trials. Trimeris, Inc. was founded in 1993 and is based in Durham, North Carolina.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.00
Volume	0
Volume Avg	0
52 Week High	0.00
52 Week Low	0.00
PE	N/A
PE (group average)	39
EPS Year	0.00
EPS change Q/Q	100%
EPS change Q/Q Yr ago	100%
EPS change Q/Q next Q est	0%
EPS change Y/Y	-42.35%
REV change Q/Q	-46.67%
REV change Q/Q Yr ago	-48.39%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%